These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 18853660)

  • 1. [Influence of antiplatelet drugs (AD) on the efectiveness of combined therapy in patients with small cell lung cancer. Part I. Influence of AD on the haemostatic system].
    Ochmański W
    Przegl Lek; 2008; 65(6):288-98. PubMed ID: 18853660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Influence of antiplatelet drugs (AD) on the efectiveness of combined therapy of small cell lung cancer. Part II. Influence of treatment on time of remission and patients survival].
    Ochmański W
    Przegl Lek; 2008; 65(7-8):321-8. PubMed ID: 19004228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effect of chemo-radiotherapy on the remission and survival in patients with limited stage small cell lung cancer].
    Bozóky G; Ruby E; Góhér I; Gábor G; Mohos A; Lengyel M
    Orv Hetil; 2005 Jul; 146(27):1433-8. PubMed ID: 16089103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
    Ohnoshi T; Hiraki S; Ueoka H; Kawahara S; Numata T; Nishii K; Yonei T; Yamashta H; Kiura K; Kozuka A
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1341-8. PubMed ID: 2543304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sequential treatment of VmP regimen and whole brain radiotherapy for small cell lung cancer patients with brain metastases].
    Yue X; Zang QC
    Ai Zheng; 2004 Dec; 23(12):1671-6. PubMed ID: 15601558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC; McCrystal MR; Christmas TI
    N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
    J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic role of coagulation in small cell lung cancers].
    LeBeau B
    Rev Mal Respir; 1996; 13(1):21-6. PubMed ID: 8650412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The treatment of small cell lung cancer].
    Li LY
    Zhonghua Zhong Liu Za Zhi; 1992 Nov; 14(6):443-6. PubMed ID: 1338986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination versus alternating chemotherapy in small-cell lung cancer.
    Lai SL; Perng RP
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jul; 63(7):513-20. PubMed ID: 10934803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High plasma D-dimer level is associated with decreased survival in patients with lung cancer.
    Altiay G; Ciftci A; Demir M; Kocak Z; Sut N; Tabakoglu E; Hatipoglu ON; Caglar T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):494-8. PubMed ID: 17513096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience.
    Shepherd FA; Ginsberg RJ; Feld R; Evans WK; Johansen E
    J Thorac Cardiovasc Surg; 1991 Mar; 101(3):385-93. PubMed ID: 1847981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing.
    Cortazar P; Gazdar AF; Woods E; Russell E; Steinberg SM; Williams J; Ihde DC; Johnson BE
    Clin Cancer Res; 1997 May; 3(5):741-7. PubMed ID: 9815744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
    Leighl NB; Goss GD; Lopez PG; Burkes RL; Dancey JE; Rahim YH; Rudinskas LC; Pouliot JF; Rodgers A; Pond GR; Shepherd FA
    Lung Cancer; 2006 Jun; 52(3):327-32. PubMed ID: 16597474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.